Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct
July 14 2020 - 9:00AM
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq:
YMAB) a late-stage clinical biopharmaceutical company focused on
the development and commercialization of novel, antibody-based
therapeutic products for the treatment of cancer, today announced
that Brian H. Santich, PhD, from Memorial Sloan Kettering (“MSK”)
will present an update on the Company’s SADA technology platform at
the Society of Nuclear Medicine and Molecular Imaging (“SNMMI”)
Virtual Annual Meeting on July 14, 2020. The SADA technology was
licensed by the Company from MSK and Massachusetts Institute of
Technology (“MIT”) earlier this year.
Dr. Santich will present how the SADA
technology’s 2-step payload delivery can be achieved in an in-vitro
setting, where tumors were shown to shrink or completely disappear,
while other tissues were spared. No clearing agent was needed, and
no significant toxicity to bone marrow, kidneys or liver tissues
was observed. We believe that the SADA technology may allow for
rapid clearance of the compound, while maintaining high target
uptake, and thereby causing less immunogenicity. In addition, the
SADA technology appears to be modular, whereby any DOTA-modified
radioactive payload combined with any therapeutic antibody seems
possible.
“We are excited about the prospects of SADA
technology, and this far we have four SADA targets in pre-clinical
development. This includes our new construct, B7-H3 SADA, which we
intend to use for the treatment of prostate cancer,” stated Thomas
Gad, Founder, Chairman and President.
Dr. Claus Moller, Chief Executive Officer,
continued, “We look forward to further advancing the SADA
technology, and plan to submit the first IND for a SADA construct
in 2021. We have high hopes to see Liquid Radiation™ transform
today’s cancer treatments.”
Researchers at MSK including Dr. Santich,
developed the SADA technology for radioimmunotherapy, which is
exclusively licensed by MSK to Y-mAbs. Dr. Santich has
intellectual property rights and interests in the technology, and
as a result of this licensing arrangement, MSK has institutional
financial interests in the technology and Y-mAbs.
About Y-mAbs
Y-mAbs is a late-stage clinical
biopharmaceutical company focused on the development and
commercialization of novel, antibody-based therapeutic products for
the treatment of cancer. The Company has a broad and advanced
product pipeline, including two pivotal-stage product candidates
naxitamab and omburtamab—which target tumors that express GD2 and
B7-H3, respectively.
Forward-Looking Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about our business model and
development and commercialization plans; current and future
clinical and pre-clinical studies and our research and development
programs; regulatory, marketing and reimbursement approvals; rate
and degree of market acceptance and clinical utility as well as
pricing and reimbursement levels; retaining and hiring key
employees; our commercialization, marketing and manufacturing
capabilities and strategy; our intellectual property position and
strategy; additional product candidates and technologies;
collaborations or strategic partnerships and the potential benefits
thereof; expectations related to the use of our cash and cash
equivalents, and the need for, timing and amount of any future
financing transaction; our financial performance, including our
estimates regarding revenues, expenses, capital expenditure
requirements; developments relating to our competitors and our
industry; and other statements that are not historical facts. Words
such as ‘‘anticipate,’’ “appear,” ‘‘believe,’’ “contemplate,”
‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’
‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’
‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will”, ‘‘would’’ and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Our product candidates and related technologies
are novel approaches to cancer treatment that present significant
challenges. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
factors, including but not limited to: risks associated with our
financial condition and need for additional capital; risks
associated with our development work; cost and success of our
product development activities and clinical trials; the risks of
delay or failure to receive approval of our drug candidates; the
risks related to commercializing any approved pharmaceutical
product including the rate and degree of market acceptance of our
product candidates; development of our sales and marketing
capabilities and risks associated with failure to obtain sufficient
reimbursement for our products; the risks related to our dependence
on third parties including for conduct of clinical testing and
product manufacture; our inability to enter into partnerships; the
risks related to government regulation; risks related to market
approval, risks associated with protection of our intellectual
property rights; risks related to employee matters and managing
growth; risks related to our common stock and other risks and
uncertainties affecting the Company including those described in
the "Risk Factors" section included in our Annual Report on Form
10-K and in our other SEC filings. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and the Company undertakes no obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Contact:
Y-mAbs Therapeutics, Inc. 230 Park Avenue, Suite 3350New York,
NY 10169USA
+1 646 885 8505
E-mail: info@ymabs.com
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Y mAbs Therapeutics (NASDAQ:YMAB)
Historical Stock Chart
From Apr 2023 to Apr 2024